CONSHOHOCKEN, PA — Tiger BioSciences positioned itself at the center of the wound care industry’s latest scientific discussions as the headline sponsor of the International Post-Acute Wound Care Society Summit (IPAWS), held November 13–14. The company used the event to showcase a data-focused strategy that it says is reshaping clinical understanding of complex wounds.
Garrett Grinsfelder, president of Tiger Wound Care, said the company’s engagement at IPAWS underscores its focus on scientific rigor and collaboration. He noted that presenting real-world evidence at the summit reflects the firm’s broader goal of equipping clinicians with tools that support better outcomes for patients with chronic and acute wounds.
In 2024, Tiger BioSciences backed five peer-reviewed retrospective manuscripts covering a range of wound types, from chronic ulcers to surgical and traumatic injuries. The studies detail the clinical use of the company’s cellular, acellular, and matrix-like products, which it describes as foundational to its technology pipeline.
The company is also advancing two randomized controlled trials evaluating ACApatch and caregraFT. Both products are being studied alongside standard treatments for venous leg ulcers, diabetic foot ulcers, and pressure ulcers — patient populations that represent some of the most persistent challenges in wound care.
Tiger BioSciences said the trials will help define how its technologies perform in controlled clinical settings, complementing the real-world data highlighted at the conference.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.